Search Results - "Natesan, Divya"

BODIPY Fluorophores for Membrane Potential Imaging by Franke, Jenna M, Raliski, Benjamin K, Boggess, Steven C, Natesan, Divya V, Koretsky, Evan T, Zhang, Patrick, Kulkarni, Rishikesh U, Deal, Parker E, Miller, Evan W

“…Fluorophores based on the BODIPY scaffold are prized for their tunable excitation and emission profiles, mild syntheses, and biological compatibility…”
Get full text

Gestational Exposure to Air Pollution Alters Cortical Volume, Microglial Morphology, and Microglia-Neuron Interactions in a Sex-Specific Manner by Bolton, Jessica L, Marinero, Steven, Hassanzadeh, Tania, Natesan, Divya, Le, Dominic, Belliveau, Christine, Mason, S N, Auten, Richard L, Bilbo, Staci D

“…Microglia are the resident immune cells of the brain, important for normal neural development in addition to host defense in response to inflammatory stimuli…”
Get full text

Definitive Chemoradiotherapy for Vulvar Cancer by Natesan, Divya, Susko, Matthew, Havrilesky, Laura, Chino, Junzo

“…This study aimed to evaluate clinical outcomes after chemoradiation (CRT) for the definitive (nonsurgical) treatment of vulvar cancer. Women with vulvar cancer…”
Get more information

APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer by Natesan, Divya, Zhang, Li, Martell, Henry J, Jindal, Tanya, Devine, Patrick, Stohr, Bradley, Espinosa-Mendez, Carlos, Grenert, James, Van Ziffle, Jessica, Joseph, Nancy, Umetsu, Sarah, Onodera, Courtney, Turski, Michelle, Chan, Emily, Desai, Arpita, Aggarwal, Rahul, Wong, Anthony, Porten, Sima, Chou, Jonathan, Friedlander, Terence, Fong, Lawrence, Small, Eric J, Sweet-Cordero, Alejandro, Koshkin, Vadim S

“…Tumor mutational burden (TMB) and APOBEC mutational signatures are potential prognostic markers in patients with advanced urothelial carcinoma (aUC). Their…”
Get full text

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor by de Kouchkovsky, Ivan, Zhang, Li, Philip, Errol J, Wright, Francis, Kim, Daniel M, Natesan, Divya, Kwon, Daniel, Ho, Hansen, Ho, Son, Chan, Emily, Porten, Sima P, Wong, Anthony C, Desai, Arpita, Huang, Franklin W, Chou, Jonathan, Oh, David Y, Pruthi, Raj S, Fong, Lawrence, Small, Eric J, Friedlander, Terence W, Koshkin, Vadim S

“…BackgroundImmune checkpoint inhibitors (ICI) can achieve durable responses in a subset of patients with locally advanced or metastatic urothelial carcinoma…”
Get full text

Clinical Factors Associated With 30-Day Mortality Among Patients Undergoing Radiation Therapy for Brain Metastases by Natesan, Divya, Carpenter, David J., Giles, Will, Oyekunle, Taofik, Niedzwiecki, Donna, Reitman, Zachary J., Kirkpatrick, John P., Floyd, Scott R.

“…Existing brain metastasis prognostic models do not identify patients at risk of very poor survival after radiation therapy (RT). Identifying patient and…”
Get full text

Leveraging Social Media as a Thermometer to Gauge Patient and Caregiver Concerns: COVID-19 and Prostate Cancer by Loeb, Stacy, Mihalcea, Rada, Perez-Rosas, Veronica, Xu, Alex, Taylor, Jacob, Byrne, Nataliya, Walter, Dawn, Ness, Marina, Robbins, Rebecca, Zhang, Sylvia, Killeen, Trevor, Natesan, Divya, Borno, Hala T.

“…The COVID-19 pandemic dramatically impacted society and health care on a global scale. To capture the lived experience of patients with prostate cancer and…”
Get full text

Effect of Large Prostate Volume on Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy in Patients With Prostate Cancer by Natesan, Divya, Carpenter, David J., Floyd, Warren, Oyekunle, Taofik, Niedzwiecki, Donna, Waters, Laura, Godfrey, Devon, Moravan, Michael J., Lee, William Robert, Salama, Joseph K.

“…To evaluate the effect of prostate volume on outcomes after moderately hypofractionated radiation therapy (mHFRT) for prostate cancer. Prostate cancer patients…”
Get full text

PD22-10 VIRTUAL REALITY WITH BIOFEEDBACK ENHANCES TOLERABILITY OF OFFICE BASED TRANSPERINEAL PROSTATE BIOPSY by Myrga, John M., Natesan, Divya, Staniorski, Christopher J., Stencel, Michael, Jacobs, Bruce L., Davies, Benjamin J.

Get full text

Differences in real-world pembrolizumab dosing patterns (every 3 weeks versus every 6 weeks) across a large cancer center network by Natesan, Divya, Chablani, Priyanka Vinod, Wang, Hong, Jelinek, Mark, Rosenzweig, Margaret Q., Wong, Risa Liang

“…2592 Background: Pembrolizumab (pembro) is an intravenous immune checkpoint inhibitor used for anti-cancer treatment, with equivalent monotherapy dosing…”
Get full text

Evolving role of an oncology telehealth nurse at an NCI-designated cancer institute by Natesan, Divya, Old, Helen Elizabeth Elizabeth, Emmons, Aviva, Hatheway, Emily, Zafar, Yousuf, Palta, Manisha

“…Abstract only 277 Background: Oncology telehealth (TH) services may improve access, mitigate care delays, and augment care in select settings. However,…”
Get full text

Palliative Care Utilization Among Patients Receiving Radiotherapy for Brain Metastases (QI413) by Natesan, Divya, Carpenter, David, Oyekunle, Taofik, Mumm, Lawrence, Reitman, Zachary, Kirkpatrick, John, Floyd, Scott

“…1. Estimate rate of palliative care use among patients with brain metastases undergoing radiation therapy 2. Learn about how outpatient palliative care affects…”
Get full text

Cancer patient satisfaction with telehealth: Survey results from a large NCI-designated cancer institute by Natesan, Divya, Niedzwiecki, Donna, Oyekunle, Taofik, Emmons, Aviva, Zafar, Yousuf, Blitzblau, Rachel

“…Abstract only 1579 Background: Telehealth (TH) utilization for patients at our cancer institute increased in 2020 in response to the COVID-19 pandemic, however…”
Get full text

Efficacy outcomes and biomarker analysis from phase II trial of escalating doses of neoadjuvant atezolizumab in patients with muscle-invasive urothelial carcinoma ineligible for cisplatin-based chemotherapy by Koshkin, Vadim S, Jindal, Tanya, He, Jun Yan, Zhang, Li, Galang, Celine N., Natesan, Divya, Kumar, Vipul, Zhu, Xiaolin, Chou, Jonathan, Aggarwal, Rahul Raj, Small, Eric J., Meng, Maxwell, Porten, Sima P., Oh, David Yoonsuk, Fong, Lawrence, Friedlander, Terence W.

“…602 Background: There are no current standard of care options for patients (pts) with muscle-invasive bladder cancer (MIBC) ineligible for cisplatin-based…”
Get full text

Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma by Proctor, Lily, Hoang, Lien, Moore, Jocelyn, Thompson, Emily, Leung, Samuel, Natesan, Divya, Chino, Junzo, Gilks, Blake, McAlpine, Jessica N

“…Vulvar squamous cell carcinoma develops through two separate pathways, associated with the presence or absence of high-risk human papilloma virus (HPV). The…”
Get more information

Low contralateral neck recurrence risk with ipsilateral neck radiotherapy in N2b tonsillar squamous cell carcinoma by Natesan, Divya, Cramer, Christina K., Oyekunle, Taofik, Niedzwiecki, Donna, Brizel, David M., Mowery, Yvonne M.

“…•Many cT1-2N0-2b tonsil cancer patients are treated with ipsilateral neck radiation.•Most with ipsilateral radiation had limited primary extension and…”
Get full text

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study by Koshkin, Vadim S., Henderson, Nicholas, James, Marihella, Natesan, Divya, Freeman, Dory, Nizam, Amanda, Su, Christopher T., Khaki, Ali Raza, Osterman, Chelsea K., Glover, Michael J., Chiang, Ryan, Makrakis, Dimitrios, Talukder, Rafee, Lemke, Emily, Olsen, T. Anders, Jain, Jayanshu, Jang, Albert, Ali, Alicia, Jindal, Tanya, Chou, Jonathan, Friedlander, Terence W., Hoimes, Christopher, Basu, Arnab, Zakharia, Yousef, Barata, Pedro C., Bilen, Mehmet A., Emamekhoo, Hamid, Davis, Nancy B., Shah, Sumit A., Milowsky, Matthew I., Gupta, Shilpa, Campbell, Matthew T., Grivas, Petros, Sonpavde, Guru P., Kilari, Deepak, Alva, Ajjai S.

“…Background Enfortumab vedotin (EV) is a novel antibody‐drug conjugate approved for advanced urothelial cancer (aUC) refractory to prior therapy. In the…”
Get full text

Researcher experience and comfort with telemedicine and remote patient monitoring in cancer treatment trials by Lichtenstein, Morgan RL, Levit, Laura, Schenkel, Caroline, Kirkwood, Margaret Kelsey, Kelley, Michael J., Mailman, Josh, Magnuson, Allison, Mirda, Daniel P., Natesan, Divya, Fashoyin-Aje, Lola A., Hershman, Dawn L.

“…385 Background: Since the onset of COVID-19, oncology practices across the U.S. have integrated telemedicine (TM) and remote patient monitoring (RPM) into…”
Get full text

Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy by Koshkin, Vadim S, Natesan, Divya, Zhang, Li, Oh, David Yoonsuk, Porten, Sima P., Meng, Maxwell, Pruthi, Raj, Aggarwal, Rahul Raj, Small, Eric Jay, Fong, Lawrence, Friedlander, Terence W.

“…Abstract only 442 Background: For patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy (cisplatin),…”
Get full text

Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials by Lichtenstein, Morgan R L, Levit, Laura A, Schenkel, Caroline, Kirkwood, Kelsey, Fashoyin-Aje, Lola A, Bruinooge, Suanna S, Kelley, Michael J, Mailman, Josh A, Magnuson, Allison, Mirda, Daniel P, Natesan, Divya, Hershman, Dawn L

“…Since the onset of COVID-19, oncology practices across the US have integrated telemedicine (TM) and remote patient monitoring (RPM) into routine care and…”
Get full text